Clinical Trials Details

A081801 ALCHEMIST - SUBSTUDY (Lung)

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Objective

Key eligibility: NSCLC - any histologic subtype; Stage IIA, IIB, IIIA or IIIB; R0; EGFR & ALK negative; 30-77 days post-op; registered to A151216. 

» Learn more about this trial

Clinical Trial Categories

  • Cancers and Other Neoplasms